(Q35880931)

10 August 2017

1 reference

title

The renal protective effects of angiotensin II receptor blockers in type 2 diabetes mellitus (English)

1 reference

10 August 2017

1 reference

2

Stephanie F Gardner

1 reference

10 August 2017

James D Coyle

1

1 reference

10 August 2017

C Michael White

series ordinal

3

1 reference

10 August 2017

language of work or name

English

0 references

publication date

7 September 2004

1 reference

Annals of Pharmacotherapy

10 August 2017

published in

1 reference

10 August 2017

volume

38

1 reference

10 August 2017

issue

10

1 reference

10 August 2017

page(s)

1731-1738

1 reference

Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001

10 August 2017

cites work

1 reference

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure<SUBTITLE>The JNC 7 Report</SUBTITLE>

21 January 2018

1 reference

Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group

21 January 2018

1 reference

Prevalence of high blood pressure and elevated serum creatinine level in the United States: findings from the third National Health and Nutrition Examination Survey (1988-1994).

21 January 2018

1 reference

Slowing the progression of renal disease in diabetic patients

21 January 2018

1 reference

Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators

21 January 2018

1 reference

Renoprotective effects of blockade of angiotensin II AT1 receptors in an animal model of type 2 diabetes

21 January 2018

1 reference

Oxidative stress and nitric oxide synthase in rat diabetic nephropathy: effects of ACEI and ARB.

21 January 2018

1 reference

The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes

21 January 2018

1 reference

Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect

21 January 2018

1 reference

Markov modeling analysis of health and economic outcomes of therapy with valsartan versus amlodipine in patients with type 2 diabetes and microalbuminuria

21 January 2018

1 reference

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

21 January 2018

1 reference

An economic evaluation of irbesartan in the treatment of patients with type 2 diabetes, hypertension and nephropathy: cost-effectiveness of Irbesartan in Diabetic Nephropathy Trial (IDNT) in the Belgian and French settings

21 January 2018

1 reference

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

21 January 2018

1 reference

Losartan in patients with type 2 diabetes and proteinuria: observations from the RENAAL Study

21 January 2018

1 reference

Induction of p27KIP1 after unilateral ureteral obstruction is independent of angiotensin II.

21 January 2018

1 reference

Losartan reduces the costs associated with diabetic end-stage renal disease: the RENAAL study economic evaluation

21 January 2018

1 reference

Analysis of Metabolic Parameters as Predictors of Risk in the RENAAL Study

21 January 2018

1 reference

Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study

21 January 2018

1 reference

The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL study

21 January 2018

1 reference

Irbesartan reduces the albumin excretion rate in microalbuminuric type 2 diabetic patients independently of hypertension: a randomized double-blind placebo-controlled crossover study.

21 January 2018

1 reference

Additive effect of ACE inhibition and angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy

21 January 2018

1 reference

Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy

21 January 2018

1 reference

Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1345/APH.1E182

1 reference

10 August 2017

1 reference